Segall Bryant & Hamill, LLC Denali Therapeutics Inc. Transaction History
Segall Bryant & Hamill, LLC
- $7.07 Billion
- Q4 2024
A detailed history of Segall Bryant & Hamill, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 289,075 shares of DNLI stock, worth $5.99 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
289,075Holding current value
$5.99 Million% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
241Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$273 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$255 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$249 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$204 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$114 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.78B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...